131 related articles for article (PubMed ID: 7654429)
41. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
42. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
43. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
Kunitoh H; Watanabe K; Onoshi T; Furuse K; Niitani H; Taguchi T
J Clin Oncol; 1996 May; 14(5):1649-55. PubMed ID: 8622084
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi Y; Taguchi T
Br J Cancer; 1999 May; 80(3-4):438-43. PubMed ID: 10408850
[TBL] [Abstract][Full Text] [Related]
45. [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].
Taguchi T; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J; Hirabayashi N
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1915-24. PubMed ID: 9797814
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Miller VA; Rigas JR; Francis PA; Grant SC; Pisters KM; Venkatraman ES; Woolley K; Heelan RT; Kris MG
Cancer; 1995 Feb; 75(4):968-72. PubMed ID: 7842417
[TBL] [Abstract][Full Text] [Related]
47. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
48. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
49. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
[TBL] [Abstract][Full Text] [Related]
51. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial.
Hainsworth JD; Burris HA; Litchy S; Morrissey LH; Barton JH; Bradof JE; Greco FA
Cancer; 2000 Jul; 89(2):328-33. PubMed ID: 10918162
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
Zekri JM; Hough RE; Davies JM; Molife R; Hancock BW; Lorigan PC
Br J Cancer; 2003 May; 88(9):1335-8. PubMed ID: 12778057
[TBL] [Abstract][Full Text] [Related]
53. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
Sanson M; Napolitano M; Yaya R; Keime-Guibert F; Broët P; Hoang-Xuan K; Delattre JY
J Neurooncol; 2000 Dec; 50(3):245-9. PubMed ID: 11263504
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
55. [Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer].
Pawlicki M; Rolski J; Zemełka T; Utych G; Wiczyńska B; Rysz B
Przegl Lek; 2001; 58(2):59-60. PubMed ID: 11475843
[TBL] [Abstract][Full Text] [Related]
56. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
Papakostas P; Kouroussis C; Androulakis N; Samelis G; Aravantinos G; Kalbakis K; Sarra E; Souglakos J; Kakolyris S; Georgoulias V
Eur J Cancer; 2001 Oct; 37(15):1833-8. PubMed ID: 11576836
[TBL] [Abstract][Full Text] [Related]
57. Docetaxel (Taxotere) administered in weekly schedules.
Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
Kavanagh JJ; Kudelka AP; de Leon CG; Tresukosol D; Hord M; Finnegan MB; Kim EE; Varma D; Forman A; Cohen P; Edwards CL; Freedman RS; Verschraegen CF
Clin Cancer Res; 1996 May; 2(5):837-42. PubMed ID: 9816238
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
[TBL] [Abstract][Full Text] [Related]
60. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel.
Schöffski P; Weihkopf T; Ganser A
Anticancer Res; 1998; 18(6B):4751-6. PubMed ID: 9891552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
